Pediatric non-Hodgkin's lymphoma

被引：26

作者：

Gross T.G. ^{[1
]}

Termuhlen A.M. ^{[1
]}

机构：

[1] Department of Pediatrics, The Ohio State University School of Medicine, Division of Hematology/Oncology/BMT, Columbus, OH 43205

来源：

Current Oncology Reports | 2007年 / 9卷 / 6期

关键词：

Anaplastic Lymphoma Kinase; Malt Lymphoma; Burkitt Lymphoma; Prophylactic Cranial Irradiation; Lymphoblastic Lymphoma;

D O I：

10.1007/s11912-007-0064-6

中图分类号：

学科分类号：

摘要：

Non-Hodgkin's lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually. NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes. Although more than 90% of pediatric NHL is of high-grade histology, more than 80% of patients achieve long-term event-free survival with modern therapy. This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：459 / 465

页数：6

共 50 条

[1]

Sandlund J.T., Downing J.R., Crist W.M., Non-Hodgkin's lymphoma in childhood, N Engl J Med, 334, pp. 1238-1248, (1996)

[2]

Gross T.G., Shiramizu B., Lymphoproliferative disorders related to immunodeficiencies, Pediatric Lymphomas, pp. 233-258, (2007)

[3]

Seidemann K., Tiemann M., Henze G., Et al., Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: Analysis of 19 patients from the BFM trials, Med Pediatr Oncol, 33, pp. 536-544, (1999)

[4]

Gross T.G., Bucuvalas J.C., Park J.R., Et al., Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation, J Clin Oncol, 23, pp. 6481-6488, (2005)

[5]

Murphy S.B., Fairclough D.L., Hutchison R.E., Et al., Non-Hodgkin's lymphomas of childhood: An analysis of the histology, staging, and response to treatment of 338 cases at a single institution, J Clin Oncol, 7, pp. 186-193, (1989)

[6]

Sabesan V., Cairo M.S., Lones M.A., Et al., Assessment of minimal residual disease in childhood non-Hodgkin lymphoma by polymerase chain reaction using patient-specific primers, J Pediatr Hematol Oncol, 25, pp. 109-113, (2003)

[7]

Campana D., Coustan-Smith E., Sandlund J.T., Abromowitch M., A novel approach for staging and minimal residual disease detection in patients with T-cell lymphoblastic lymphoma: A Children's Oncology Group study, Ann Oncol, 16, SUPPL. 5, (2005)

[8]

Burkhardt B., Zimmermann M., Oschlies I., Et al., The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence, Br J Haematol, 131, pp. 39-49, (2005)

[9]

Harris N.L., Jaffe E.S., Diebold J., Et al., World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997, J Clin Oncol, 17, pp. 3835-3849, (1999)

[10]

Oschlies I., Klapper W., Zimmermann M., Et al., Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: A clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial, Blood, 107, pp. 4047-4052, (2006)

← 1 2 3 4 5 →